Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

Blood blood.2024025834.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Kateryna Fedorov, Alexander Sisto, Josette Kamel, Mark Forsberg, Kith Pradhan, Nishi Shah, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Kira Gritsman, Amit K. Verma, Eric J Feldman, Marina Y. Konopleva, Ioannis Mantzaris

Blood (2023) 142 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2023-180856

Published: 2023

Journal Articles

GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Blood (2023) 142 (Supplement 1): 318.

https://doi.org/10.1182/blood-2023-179131

Published: 2023

Journal Articles

North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351

B. Hilda Ye, Eric Liu, Kith Pradhan, Erik Guillen, Urvi A Shah, Aditi Shastri, Gregoire Lauvau, Murali Janakiram, Alejandro Sica, Paul D. Kassner, Amit Verma

Blood (2023) 142 (Supplement 1): 6108.

https://doi.org/10.1182/blood-2023-191045

Published: 2023

Journal Articles

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Blood (2023) 142 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2023-186227

Published: 2023

Journal Articles

Inhibition of Toll-like Receptor 4 (TLR4) Promotes Erythroid and Myeloid Differentiation in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Ariel Fromowitz, Srinivas Aluri, Jesus D Gonzalez Lugo, Emma Rabinovich, Nandini Ramachandra, Sarah Aminov, Srabani Sahu, Shanisha Gordon Mitchell, Ritesh Aggarwal, Opeyemi Ajibade, Milagros Carbajal, Kith Pradhan, Andrea Pellagatti, Jacqueline Boultwood, Aditi Shastri, Rongbao Zhao, Amit K. Verma

Blood (2023) 142 (Supplement 1): 5615.

https://doi.org/10.1182/blood-2023-182059

Published: 2023

Journal Articles

The Prevalence and Mutational Spectrum of Clonal Hematopoiesis in Diverse Populations in New York City

Varun Gupta, Mariko Isshiki, Anna Skwarska, Kith Pradhan, Amit K. Verma, Marina Y. Konopleva, Aditi Shastri, Srilakshmi Raj

Blood (2023) 142 (Supplement 1): 5604.

https://doi.org/10.1182/blood-2023-180973

Published: 2023

Journal Articles

Exposure to Fine Particulate Matter (PM2.5) Is Associated with Worse Multiple Myeloma Outcomes in a Large, Urban, Multi-Ethnic Cohort

Michael Wysota, Sarah Jacobs, Kith Pradhan, Joel Rosiene, Charles Hall, George Downward, Yocheved Halberstam, Nishi Shah, Dean Hosgood, Aditi Shastri

Blood (2023) 142 (Supplement 1): 531.

https://doi.org/10.1182/blood-2023-186937

Published: 2023

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2023-186947

Published: 2023

Journal Articles

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML

Nandini Ramachandra, Charan Thej Reddy Vegivinti, Srabani Sahu, Bianca Rivera, Sarah Aminov, Ariel Fromowitz, Jinghang Zhang, Fnu Aodengtuya, Kith Pradhan, Rongbao Zhao, Leya Schwartz, Victor Thiruthuvanathan, Rahul Sanawar, Emma Rabinovich, Opeyemi Ajibade, Aditi Shastri, Michael Lahn, Amit K. Verma

Blood (2023) 142 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2023-179921

Published: 2023

Journal Articles

Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML

Bianca L Rivera, Samarpana Chakraborty, Yang Shi, Hui Zhang, Gaurav S Choudhary, Shanisha Gordon, Kith Pradhan, Bowen Fu, Isidora Tosic, Rongbao Zhao, Mendel Goldfinger, Ioannis Mantzaris, Milagros Carbajal, Nandini Ramachandra, Marina Konopleva, David Frank, Yogenthiran Saunthararajah, Amit Verma, Aditi Shastri

Blood (2022) 140 (Supplement 1): 6892–6893.

https://doi.org/10.1182/blood-2022-163255

Published: 2022

Journal Articles

Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress

B. Hilda Ye, Elaine Chung, Xiaoxin Ren, Kith Pradhan, Yanhua Wang, Advaitha Madireddy, Xingxing Zang, Murali Janakiram, R. Alejandro Sica, Amit Verma

Blood (2022) 140 (Supplement 1): 8764–8765.

https://doi.org/10.1182/blood-2022-170425

Published: 2022

Journal Articles

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Blood (2022) 140 (Supplement 1): 10949–10950.

https://doi.org/10.1182/blood-2022-164841

Published: 2022

Journal Articles

Effects of Autoimmune Disease on Non-High Risk MDS Outcomes: A Population Analysis

Rohit Singh, David Alfonso Alejos Castillo, Akshee Batra, Andrew D Sparks, Aditi Shastri, Kith Pradhan, Neil Zakai, Diego Adrianzen Herrera

Blood (2022) 140 (Supplement 1): 692–693.

https://doi.org/10.1182/blood-2022-163522

Published: 2022

Journal Articles

Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

Blood (2022) 140 (Supplement 1): 13225–13227.

https://doi.org/10.1182/blood-2022-170633

Published: 2022

Journal Articles

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

David Levitz, Kateryna Fedorov, Kith Pradhan, Lauren C Shapiro, Aditi Shastri, Kira Gritsman, Nishi Shah, Noah Kornblum, R. Alejandro Sica, Ira Braunschweig, Marina Konopleva, Eric J. Feldman, Amit Verma, Ioannis Mantzaris, Yogenthiran Saunthararajah, Mendel Goldfinger

Blood (2022) 140 (Supplement 1): 6218–6219.

https://doi.org/10.1182/blood-2022-170059

Published: 2022

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

Blood (2022) 140 (Supplement 1): 11595–11597.

https://doi.org/10.1182/blood-2022-159826

Published: 2022

Journal Articles

Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population

Blood (2021) 138 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2021-146532

Published: 2021

NARROW

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Inhibition of Toll-like Receptor 4 (TLR4) Promotes Erythroid and Myeloid Differentiation in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

The Prevalence and Mutational Spectrum of Clonal Hematopoiesis in Diverse Populations in New York City

Exposure to Fine Particulate Matter (PM2.5) Is Associated with Worse Multiple Myeloma Outcomes in a Large, Urban, Multi-Ethnic Cohort

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML

Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML

Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Effects of Autoimmune Disease on Non-High Risk MDS Outcomes: A Population Analysis

Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only